公开(公告)号：US11447549B2

公开(公告)日：2022-09-20

申请号：US16633740

申请日：2018-07-26

申请人： BIOINVENT INTERNATIONAL AB ,  CANCER RESEARCH TECHNOLOGY LIMITED

发明人： Björn Frendéus ,  Linda Mårtensson ,  Monika Semmrich ,  Ingrid Teige ,  Stephen Beers ,  Aymen Al-Shamkhani ,  Juliet Gray ,  Martin Glennie

IPC分类号： A61K39/395 ,  C07K16/28 ,  A61K39/00

摘要： Described is the sequential administration of first a Treg depleting antibody molecule selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti-body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. Described are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.